Delineating organs at risk in radiotherapy
DOI:
https://doi.org/10.55378/rv.46.1.5Keywords:
Radiotherapy, organs at risk, target volume, dose limitsAbstract
The goal of radiotherapy, as one of the oncology treatment procedures is tumour growth control considering possible complications on healthy tissue. It is necessary to deliver prescribed absorbed doze to the aimed area of interest while delivered doze to surrounding healthy tissue, specially organs sensitive to ionizing radiation must be as low as possible. While planning radiotherapy treatment special attention must be payed to organs at risk (OAR) to avoid pathological changes to healthy tissue with irreversible damages.
OAR-s are clearly shown by division into anatomical groups (head and neck, chest, abdominal and pelvic region). Their sensitivity to absorbed doze depending on their structure and division is divided into serial and parallel OAR and is described considering their tolerance to absorbed doze affects, treatment planning and prescribed tumour doze. There is a chart with doze limitations for each OAR prescribed.
To conduct radiotherapy treatment there must be a team of radiation oncologists, medical physicists and radiation technologists (RTT). Precise delineation of target volume and OAR´s is an important factor for the outcome of radiotherapy. Planning radiation therapy, isocenter determination and treatment itself are followed after target volume determination.
This article presents a multidisciplinary model with a goal to improve the quality of treatment planning.
References
Barton M.B., Jacob S., Shafiq J., et al. Estimating the Demand for Radiotherapy from the Evidence: A Review of Changes from 2003 to 2012. Radiother. Oncol. (2014);112(1): 140–44
Bentzen S.M., Constine L.S., Deasy J.O. et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int. J. Radiat. Oncol. Biol. Phys. (2010); 76(3): S3–S9
International Commission on Radiation Units and Measurements (ICRU), Prescribing, Recording and Reporting Photon Beam Therapy (Report 62) (1999)
International Commission on Radiation Units and Measurements Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83 J ICRU, 10 (2010), pp. 1-106
Remeijer P., Inter-observer variation in target volume delineation, ESTRO SCHOOL Moscow,2018
Shalek R.J. International Commission on Radiation Units and Measurments (ICRU) Determination of Absorbed Dose in a Patient Irradiated by Beams of X or Gamma Rays in Radiotherapy Procedures ICRU Report 24. Med. Phys. (1977); 4: 461
Mileusnić D., Marošević G., Durbaba M. Radijaciona Onkologija, 2019
Lee N.A., Riaz N., Jiade J., et.al. Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy, 2014
Giampiero A.Cefaro, Domenico Genovesi, Carlos A.Perez, Delineating Organs at Risk in Radiation Therapy, 2013
Gregory M.M.Videtic, Neil M.Woody, Handbook of Treatment Planning Radiation Oncology, 2015
Emami B., Tolerance of Normal Tissue to Therapeutic Radiation, Radiother. Oncol. (2013); 1(1)
Rogers CL, Won M, Vogelbaum MA, et al. High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):790-799.
Group RTO. A phase II study of concurrent chemoradiotherapy using three-dimensional conformal radiotherapy(3D-CRT) or inteusity-modulated radiation therapy (IMRT)+Bevaciztanab(BV) for locally or regionally advanced nasopharyngeal cancer, RTOG 0615 [2011-03-05].
Group RTO. A phase II study of intensity modulated radiation therapy (IMRT) +/−chemotherapy for nasopharyngeal cancer, RTOG 0225 [2011-03-05].
Raben D, Wong S, Galvin J, et al. RTOG 0619 Protocol: Radiation Therapy Oncology Group Rtog 0619 a Randomized Phase Ii Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck.; 2011.
Lilenbaum R, Komaki R, Martel MK. Radiation Therapy Oncology Group RTOG 0623, a Phase Ii Trial of Combined Modality Therapy With Growth Factor. Cycle. 2008.
Garofalo M, Moughan J, Hong T, Bendell J, Berger A, Lerma F, et al. RTOG 0822: A Phase II Study of Preoperative (PREOP) Chemoradiotherapy (CRT) Utilizing IMRT in Combination with Capecitabine (C) and Oxaliplatin (O) for Patients with Locally Advanced Rectal Cancer. International Journal of Radiation Oncology • Biology • Physics 2011;81:S3-S4.
Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;74: 383-387.
Michalski JM, Moughan J, Purdy J, et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018 Jun 14;4(6):e180039. doi: 10.1001/jamaoncol.2018.0039.
www.onkologymedicalphysics.com
Zhai, R. P., F. F. Kong, C. R. Du, et al. „Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study.“ Oral Oncol, 2017, 68:44-49.
Cella, L., M. Conson, M. Caterino, et al. „Thyroid V30 predicts radiation-induced hypothyroidism in patients treated with sequential chemo-radiotherapy for Hodgkin’s lymphoma.“ Int J Radiat Oncol Biol Phys, 2012, 82(5):1802-1808.
Kavanagh B.D., Pan C.C., Dawson L.A., et.al. Radiation Dose–Volume Effects in the Stomach and Small Bowel. Int. J. Radiation Oncology Biol. Phys., 2010. Vol.76, No. 3
NCCN. Guidelines Version 2. for Cervical Cancer. NCCN Evidence Bloks. http://208.251.169.72/members/protocols/0615/0615.pdf, 2020
Van der Merwe D., Van Dyk J., Healy B., et.al. Accuracy requirements and uncertainties in radiotherapy: a report of the International Atomic Energy Agency, Acta Oncologica, 2016.
Lohynska R.,Jirkovska M.,Novakova-Jiresova A., Mazana E., Vanbersky K., Veselsky T.,Kindlova A., Stankusova H., Malinova B. : Austin Journal of Cancer an Clinical Research: Proposal for Radiotherapy DOSE Constraint Predicting Uterus Fertility Sparing: Successful Pregnacy Case Report after Curative Chemoradiotherapy for Rectal Cancer, 2020.
Rashmi Jadon, Emma Higgins, John Staffurth, Louise Hanna, Mererid Evans, Bernadette Coles. ro-journal.biomedcentral.com, A systematic review of dose-volume predictors and constraints for late bowel toxicity following pelvic radiotherapy.2019.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2022 Ivan Balentović (Autor)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
CART